Ifeanyichukwu Ifechidere: DOAC Monitoring – What To Order, When, And Why
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
“Not every patient on a DOAC needs monitoring.
But when they do, ordering the wrong assay can lead to the wrong clinical decision.
This is where many clinicians-and even laboratories-get caught out.
The question isn’t just ‘Should I measure the DOAC?’
It’s ‘Which assay answers my clinical question?’
Here’s a simple way to think about it:
- Anti-Xa assay
- Best for rivaroxaban, apixaban, and edoxaban
- Use a drug-specific calibrated Anti-Xa assay
- Helpful in major bleeding, urgent surgery, suspected overdose, renal impairment, or unexpected thrombosis.
Dilute Thrombin Time (dTT)
- Best for dabigatran
- Provides a quantitative estimate of dabigatran concentration.
- More reliable than routine clotting tests.
DOAC Screen
- Useful as a rapid screening tool to determine whether a clinically significant DOAC is present.
- Helpful in emergency settings when the anticoagulant history is uncertain.
- It is not a substitute for drug-specific quantification.
And here’s the part that’s often overlooked…
Timing matters just as much as assay selection.
A result is difficult to interpret unless you know:
- Which DOAC the patient is taking
- The dose
- The time of the last dose
- Renal function
- Whether you’re measuring a peak or trough level
Without that context, even the ‘right’ test can produce a misleading interpretation.
The takeaway:
The goal of DOAC testing isn’t simply to detect the drug.
It’s to answer a specific clinical question with the right assay at the right time.
What is the biggest challenge your laboratory or clinical team faces when interpreting DOAC assays?”

Find more posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
Aug 16, 2026, 13:05Neil Morgan: Submit Your Abstract for BSHT 2027
-
Aug 16, 2026, 12:50Heba Youssef: Can Cefoperazone Cause Coagulopathy?
-
Aug 16, 2026, 12:35Mohammad Alkhalil: Stroke Remains a Dreaded Complication in TAVI
-
Aug 16, 2026, 12:16Jeff Schaffnit: The Power of Community in Rare Blood Disorders
-
Aug 16, 2026, 12:03Fawaz AlOtaibi: Can AI Replace Contrast CTA for Vascular Screening?
-
Aug 16, 2026, 10:31Erhabor Osaro: Critical Issues to Consider During the Clinical Blood Transfusion Process
-
Aug 16, 2026, 10:14Juan Manuel Cisneros Carrasco: The Architects Behind the Blood Donation System
-
Aug 16, 2026, 10:06Honoring the Life and Legacy of Dr. Reed Pyeritz – GADA Canada
-
Aug 16, 2026, 09:51Javier Amador-Castañeda: When a 32 Percent Reduction Tells Only Part of the Story